OZYMD Projected Dividend Yield
Orphazyme A/S ( OTCBB : OZYMD )Orphazyme is a late-stage biopharmaceutical company harnessing the amplification of Heat Shock Proteins, or HSPs, in order to develop and commercialize novel therapeutics for the treatment of neurodegenerative rare diseases. Co.'s product candidate, arimoclomol is an orally- or naso/gastrically-administered small molecule that crosses the blood-brain barrier and is designed to selectively amplify the natural role of endogenous HSPs, which protect against cellular toxicity caused by protein misfolding, aggregation and lysosomal dysfunction. Co. is also developing arimoclomol for the treatment of neurological manifestations of Gaucher disease. 21 YEAR PERFORMANCE RESULTS |
OZYMD Dividend History Detail OZYMD Dividend News OZYMD Competitors News |
Year |
Declaration Date |
Ex-Dividend Date |
Record Date |
Payable Date |
Dividend $ Amount |
Total: |
0.0000 |